Security Snapshot

abrdn Life Sciences Investors - Common (HQL) Institutional Ownership

CUSIP: 87911K100

13F Institutional Holders and Ownership History from Q3 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

73

Shares (Excl. Options)

8,775,215

Price

$16.78

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common
Symbol
HQL on NYSE
Shares outstanding
29,948,325
Price per share
$16.95
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
8,775,215
Total reported value
$147,088,649
% of total 13F portfolios
0%
Share change
-460,356
Value change
-$7,099,873
Number of holders
73
Price from insider filings
$16.95
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • HQL - abrdn Life Sciences Investors - Common is tracked under CUSIP 87911K100.
  • 73 institutions reported positions in Q4 2025.
  • 2 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 73 to 68 between Q4 2025 and Q1 2026.
  • Reported value moved from $147,088,649 to $69,705,504.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 73 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 87911K100?
CUSIP 87911K100 identifies HQL - abrdn Life Sciences Investors - Common in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of abrdn Life Sciences Investors - Common (HQL) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FIRST TRUST PORTFOLIOS LP 10% +63% $51,853,848 +$20,500,606 3,021,786 +65% First Trust Portfolios L.P. 28 Feb 2026
Saba Capital Management, L.P. 5% -12% $24,978,587 -$3,801,582 1,464,161 -13% Saba Capital Management, L.P. 19 Feb 2026

As of 31 Dec 2025, 73 institutional investors reported holding 8,775,215 shares of abrdn Life Sciences Investors - Common (HQL). This represents 29% of the company’s total 29,948,325 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of abrdn Life Sciences Investors - Common (HQL) together control 27% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Saba Capital Management, L.P. 7.1% 2,117,174 -18% 1.2% $35,526,180
MORGAN STANLEY 3.9% 1,164,826 +34% 0% $19,545,813
Penserra Capital Management LLC 2.9% 875,126 +10% 0.17% $14,684,000
RAYMOND JAMES FINANCIAL INC 2% 597,055 +41% 0% $10,018,597
LPL Financial LLC 1.5% 448,846 +20% 0% $7,531,642
NEEDHAM INVESTMENT MANAGEMENT LLC 1.3% 403,364 0% 0.43% $6,768,448
FLAGSHIP HARBOR ADVISORS, LLC 1.2% 363,381 +1.8% 0.29% $6,097,550
Allspring Global Investments Holdings, LLC 0.77% 230,437 -2.1% 0.01% $3,866,733
RIVERNORTH CAPITAL MANAGEMENT, LLC 0.66% 198,730 -35% 0.16% $3,334,690
AMERIPRISE FINANCIAL INC 0.64% 190,648 -9.1% 0% $3,199,756
Advisors Asset Management, Inc. 0.56% 168,334 +5.8% 0.05% $2,824,645
180 WEALTH ADVISORS, LLC 0.52% 154,325 +3.4% 0.29% $2,589,577
Formidable Asset Management, LLC 0.42% 124,445 +63% 0.28% $1,930,136
Shaker Financial Services, LLC 0.39% 115,419 -42% 0.61% $1,936,731
1607 Capital Partners, LLC 0.38% 115,070 -5.8% 0.13% $1,930,875
BANK OF AMERICA CORP /DE/ 0.36% 106,440 -5.8% 0% $1,786,067
ROYAL BANK OF CANADA 0.35% 104,074 +31% 0% $1,745,000
World Investment Advisors 0.33% 99,520 +7.2% 0.03% $1,669,943
WOLVERINE ASSET MANAGEMENT LLC 0.32% 97,122 -55% 0.02% $1,629,707
Janney Montgomery Scott LLC 0.29% 87,853 +6.7% 0% $1,474,000
BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC 0.26% 77,070 +19% 0.19% $1,293,235
UHLMANN PRICE SECURITIES, LLC 0.25% 76,138 +3% 0.76% $1,277,494
LANDSCAPE CAPITAL MANAGEMENT, L.L.C. 0.23% 69,030 0.08% $1,158,323
Z3 Capital Partners, LLC 0.22% 66,849 0% 0.27% $1,121,726
Private Advisor Group, LLC 0.21% 64,227 +0.85% 0.01% $1,077,720

Institutional Holders of abrdn Life Sciences Investors - Common (HQL) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 4,278,983 $69,705,504 +$3,242,172 $16.27 68
2025 Q4 8,775,215 $147,088,649 -$7,099,873 $16.78 73
2025 Q3 9,135,304 $141,452,290 -$612,075 $15.51 82
2025 Q2 9,160,432 $117,354,763 +$3,718,136 $12.81 75
2025 Q1 8,871,741 $112,593,442 -$7,767,200 $12.69 82
2024 Q4 9,477,441 $124,355,615 -$6,077,782 $13.12 72
2024 Q3 9,873,051 $148,865,144 +$3,496,897 $15.08 74
2024 Q2 9,607,549 $136,221,681 +$7,416,967 $14.17 75
2024 Q1 9,097,810 $123,989,537 +$15,543,590 $13.63 79
2023 Q4 7,957,094 $107,172,259 +$20,629,421 $13.46 79
2023 Q3 6,434,689 $80,230,199 +$11,333,847 $12.47 79
2023 Q2 5,495,691 $74,402,090 +$3,747,676 $13.54 78
2023 Q1 5,218,628 $72,689,568 +$181,766 $13.93 78
2022 Q4 5,215,082 $74,160,302 +$13,461,137 $14.21 79
2022 Q3 4,273,316 $58,377,986 +$8,412,428 $13.66 59
2022 Q2 3,670,943 $52,261,963 +$42,180 $14.23 63
2022 Q1 3,659,571 $60,566,148 -$3,857,113 $16.54 62
2021 Q4 3,874,395 $74,397,923 -$4,344,897 $19.23 62
2021 Q3 4,078,867 $85,055,000 -$6,796,791 $20.80 60
2021 Q2 4,393,839 $94,224,459 -$7,765,396 $21.44 62
2021 Q1 4,759,098 $93,769,016 -$3,063,175 $19.71 59
2020 Q4 4,901,740 $96,913,930 +$4,277,094 $19.75 61
2020 Q3 4,667,693 $82,119,114 +$2,719,515 $17.58 56
2020 Q2 4,593,229 $82,470,887 +$2,418,762 $17.96 65
2020 Q1 4,348,971 $65,182,146 +$3,312,576 $14.98 64
2019 Q4 4,081,292 $71,163,712 +$10,150,880 $17.43 62
2019 Q3 3,306,970 $50,015,468 +$2,019,469 $15.10 56
2019 Q2 3,165,675 $53,305,158 -$107,682 $16.85 50
2019 Q1 3,197,807 $54,748,908 -$880,173 $17.13 51
2018 Q4 3,256,357 $49,207,495 +$630,267 $15.11 53
2018 Q3 3,162,453 $64,565,945 -$620,909 $20.42 53
2018 Q2 3,204,169 $60,229,278 +$400,395 $18.79 57
2018 Q1 3,180,291 $60,941,490 +$2,123,352 $19.21 54
2017 Q4 3,055,824 $60,046,863 +$2,780,074 $19.63 53
2017 Q3 2,690,191 $57,884,029 +$5,149,401 $21.48 50
2017 Q2 2,450,878 $51,124,000 -$30,093 $20.85 43
2017 Q1 2,461,431 $47,583,000 -$1,650,891 $19.39 39
2016 Q4 2,565,495 $43,758,000 +$3,771,229 $16.99 44
2016 Q3 2,171,425 $40,653,000 -$924,995 $18.73 41
2016 Q2 2,226,005 $38,335,000 -$3,729,087 $17.19 46
2016 Q1 2,417,731 $43,421,000 -$4,199,541 $17.94 42
2015 Q4 2,618,012 $61,825,000 +$3,683,007 $23.64 46
2015 Q3 2,464,547 $55,596,000 +$3,050,178 $22.51 42
2015 Q2 2,302,053 $64,980,792 +$5,330,725 $28.21 41
2015 Q1 2,111,627 $58,177,144 -$947,913 $27.57 39
2014 Q4 2,150,612 $53,523,700 +$51,463,341 $24.88 38
2014 Q3 2,881 $64,000 +$64,000 $22.15 2
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .